Author: Lynk Pharmaceuticals Co., Ltd.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

June 9, 2026
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment’s Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

June 1, 2026

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor